Great Stocks: Valeant Pharmaceuticals Near Buy Point
at Investor's Business Daily - Tue Dec 16, 5:11PM CST
Drugmaker Valeant Pharmaceuticals is working on a new base as it prepares to issue its 2015 financial outlook. The base's cup-with-handle pattern shows a potential buy point at 147.49. But it's a risky, late-stage pattern, forming after the stock had...
AGN: 205.75 (-3.26), ACT: 256.52 (-6.48), VRX: 136.92 (-1.24)
Allergan Set to Possibly Rebound After Yesterday's Selloff of 1.29%
Comtex SmarTrend(R) - Tue Dec 16, 4:06PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $206.08 to a high of $209.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $208.47 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 205.75 (-3.26)
Allergan (AGN) Approaches New Downside Target of $207.30
Comtex SmarTrend(R) - Tue Dec 16, 11:40AM CST
Allergan (AMEX:AGN) has opened bearishly below the pivot of $209.57 today and has reached the first level of support at $208.16. Investors may be interested in a cross of the next downside pivot targets of $207.30 and $205.03.
AGN: 205.75 (-3.26)
Actavis unveils post-Allergan management structure
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 8:33AM CST
AGN: 205.75 (-3.26), ACT: 256.52 (-6.48)
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition
PR Newswire - Tue Dec 16, 6:30AM CST
Actavis plc (NYSE: ACT) today announced the planned senior management team that will lead the global pharmaceutical company following the successful close of the acquisition of Allergan, Inc., anticipated in the second quarter of 2015. Brent Saunders will continue to lead Actavis as CEO and President and a member of the Board of Directors. Paul Bisaro will remain Executive Chairman of the Board of Directors. Mr. Saunders will lead an expanded senior management team comprised of leaders from both Actavis and Allergan, designed to further enhance the Company's position as the fastest growing and most dynamic growth pharmaceutical company in global healthcare.
AGN: 205.75 (-3.26), ACT: 256.52 (-6.48)
New Research from Allergan Reveals that the Quest to Look Younger is No Longer a Beauty Priority for Women
PR Newswire Europe - Tue Dec 16, 1:31AM CST
MARLOW, England, December 16, 2014 /PRNewswire/ --
AGN: 205.75 (-3.26)
Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015
at The Street - Mon Dec 15, 8:27AM CST
With 2014 nearly over, the question now becomes which stocks, sectors and strategies billionaire investors will be betting on in 2015. A few predictions.
VIPS: 19.83 (-0.67), ACT: 256.52 (-6.48), F: 14.09 (-0.19), TLM: 7.58 (+2.46), AXP: 88.24 (-1.80), ATLS: 25.41 (-0.33), AET: 85.64 (-1.03), ENR: 127.00 (+1.23), ZTS: 40.85 (-0.89), AGN: 205.75 (-3.26), V: 253.41 (-3.29), GMO: 0.34 (+0.04), RIG: 16.78 (+0.53), EBAY: 55.94 (+0.50), THC: 48.36 (-0.90), BAX: 70.73 (-0.37), CHK: 17.45 (+0.23), AAL: 47.96 (-2.88), GM: 30.73 (-0.27), IDIX: 24.50 (+0.05), MA: 82.64 (-1.97)
Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 91.05 (-1.12), MDVN: 102.50 (-1.58), CNC: 101.19 (-1.75), AGN: 205.75 (-3.26), VRTX: 110.86 (-2.02), ALNY: 92.08 (-1.87), EW: 125.44 (-1.57), ILMN: 175.18 (-3.13), SNY: 45.38 (+0.98), REGN: 396.13 (-4.88), PBYI: 195.44 (+0.11)
Uptrend Call Working As Allergan Stock Rises 24.8% (AGN)
Comtex SmarTrend(R) - Fri Dec 12, 4:49PM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 3 months, Allergan has returned 24.75% as of today's recent price of $208.47.
AGN: 205.75 (-3.26)
After Yesterday's Decline of 1.26%, Allergan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Dec 12, 4:03PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $208.47 to a high of $210.59. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $209.85 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 205.75 (-3.26)
Cerebral Palsy - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdwf83/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Allergan - Acorda Therapeutics, Inc. - Neuralstem, Inc. - CHA Bio & Diostech Co., Ltd. - K-Stemcell Co., Ltd. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. For more information visit http://www.researchandmarkets.com/research/zd...bral_palsy
AGN: 205.75 (-3.26), ACOR: 38.25 (-0.15), CBMG: 12.84 (-0.75), CUR: 2.37 (-0.02)
Merck Reveals Data from Breast Cancer Study on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 4:10PM CST
Merck (MRK) announced early data from the phase Ib study on its anti-PD-1 therapy, Keytruda.
AGN: 205.75 (-3.26), MRK: 56.80 (-0.15), BMY: 57.69 (-0.86)
Wilshire Confirms First-to-File Patent Challenge Relating to LASTACAFT®
PR Newswire - Thu Dec 11, 2:18PM CST
Wilshire Pharmaceuticals, Inc. ("Wilshire"
AGN: 205.75 (-3.26)
Roche (RHHBY) Presents Positive Data on Haemophilia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:16PM CST
Roche (RHHBY) announced data on its pipeline candidate ACE910 at the 56th American Society of Hematology.
AGN: 205.75 (-3.26), ABBV: 65.25 (-0.37), BIOD: 1.30 (-0.02)
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Wed Dec 10, 11:17AM CST
BDX: 134.04 (-1.71), BCR: 165.84 (-0.37), AXP: 88.24 (-1.80), TMO: 121.55 (-2.18), WBK: 25.91 (+0.05), AMT: 95.78 (-1.67), C: 51.17 (-1.62), AMGN: 159.44 (-0.16), CELG: 110.09 (-1.79), MCO: 92.38 (-1.41), AGN: 205.75 (-3.26), T: 32.14 (-0.11), GS: 183.31 (-2.23), JPM: 58.43 (-0.73), GILD: 100.46 (-2.70), MMP: 75.80 (-0.77)
The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan
PR Newswire - Wed Dec 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Novartis (NYSE:NVS-Free Report), Amgen (Nasdaq:AMGN-Free Report), Incyte Corp. (Nasdaq:INCY-Free Report) and Allergan (NYSE:AGN-Free Report).
AGN: 205.75 (-3.26), INCY: 71.62 (-0.52), AMGN: 159.44 (-0.16), NVS: 91.65 (+0.01)
Herb Greenberg: What's Next for Valeant After Its Botched Bid for Allergan
at The Street - Wed Dec 10, 8:18AM CST
Has the pharmaceutical company really changed its strategy?
AGN: 205.75 (-3.26), VRX: 136.92 (-1.24)
Jim Cramer on the Stock Market: Activists Give Up on the Losers
at The Street - Wed Dec 10, 7:48AM CST
And that's too bad, because United Tech and McDonald's are begging for turnarounds.
AGN: 205.75 (-3.26), GE: 24.49 (-0.10), UTX: 113.23 (+1.32), MCD: 88.72 (+0.26), DOW: 42.71 (-0.74), WEN: 8.51 (-0.11), PEP: 92.59 (-1.55), BKW: 35.50 (-1.16)
Jim Cramer's 'Mad Money' Recap: Why Tuesday's Market Decline Made Sense
at The Street - Tue Dec 09, 7:32PM CST
The international markets pulled U.S. stocks lower but they were able to bounce back despite bad news from Verizon, Bank of America and Citi.
EA: 45.45 (unch), HON: 96.38 (+0.57), UTX: 113.23 (+1.32), C: 51.17 (-1.62), SNE: 19.72 (unch), BBY: 35.77 (-1.14), PEP: 92.59 (-1.55), AGN: 205.75 (-3.26), ATVI: 19.38 (-0.64), ETP: 61.46 (+2.14), SAVE: 68.70 (+0.11), TRGP: 91.28 (+0.42), WMB: 41.84 (-0.30), TEX: 25.66 (-0.45), AYR: 19.71 (-0.12), CAT: 89.34 (-0.41), MSFT: 45.16 (-1.51), UNP: 112.20 (-0.14), GME: 31.92 (-1.01), PDS: 5.57 (+0.22), BAC: 16.72 (-0.13), BKW: 35.50 (-1.16), MHR: 3.12 (+0.28), CONN: 14.15 (-1.63), MRK: 56.80 (-0.15), FLS: 54.90 (+0.10), MCD: 88.72 (+0.26), BRK.B: 145.28 (-0.84), VZ: 45.53 (+0.11), AMFW: 12.71 (+0.46), NRG: 25.83 (-0.29), WEN: 8.51 (-0.11)
Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 2:15PM CST
Novartis (NVS) announced that its generic arm, Sandoz, reported encouraging data from a phase III study, PIONEER.
AGN: 205.75 (-3.26), INCY: 71.62 (-0.52), AMGN: 159.44 (-0.16), NVS: 91.65 (+0.01)